Adverse Effects of Gliptins in Type 2 Diabetics in Morocco.
| Autor: | Guerboub AA; Endocrinology Department, Faculty of Medicine and Pharmacy, Mohammed V Military Academic Hospital, Mohammed V-Souissi University, Rabat, Morocco., Louday L, Issouani J, Errahali Y |
|---|---|
| Jazyk: | French; English |
| Zdroj: | Annals of African medicine [Ann Afr Med] 2024 Oct 01; Vol. 23 (4), pp. 606-610. Date of Electronic Publication: 2024 Aug 13. |
| DOI: | 10.4103/aam.aam_35_24 |
| Abstrakt: | Introduction: Gliptins are a relatively recent class of oral antidiabetic agents used in the treatment of type 2 diabetes. The aim of this study is to identify the adverse effects of gliptins in patients with type 2 diabetes, compare the tolerability of these drugs with data from the literature, and determine patients' behavior in the face of these adverse effects with a view to optimizing their management. Methods: Our study is cross-sectional, descriptive, and analytical, involving 100 patients aged over 20 years, followed at the Endocrinology Department of the Military Hospital Mohammed V. Results: The average age of the patients was 63 years, with a sex ratio F/H of 1.13. The median age of diabetes in the patients was 13 years, with an average blood glucose level of 1.64 and an average hemoglobin A1c of 8.26. The comorbidities were 30% cardiovascular disease, 25% hypertension, and 14% dyslipidemia, and 30% of patients had no comorbidities. Forth-six percent of patients reported adverse events and 54% did not report any adverse event. Twenty-eight percent of the adverse events were gastrointestinal, 18% skin disorders, 14% urinary tract infections, 12% hypoglycemia, 12% nervous system disorders, 8% airway infections, and 8% general disorders. Conclusion: This study shows that gliptins remain a safe option as the side effects seem fairly well tolerated by patients. Adverse events may impact patient compliance and pose a problem of adherence to treatment. Thus, it would be advantageous to develop therapeutic education for diabetic patients to detect and manage adverse effects. (Copyright © 2024 Copyright: © 2024 Annals of African Medicine.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|